Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP46A1 | Q9Y6A2 | 13/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | USP7 | Q93009 | 1/20 | 0.32 |
| ▸ | CCR5 | P51681 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21215199 | 0.81 | CYP46A1 (0.62) | CYP46A1CYP3A4CYP2C9CYP2C19CYP2C8 | |
| SCHEMBL20792873 | 0.77 | CYP46A1 (0.39) | CYP46A1CYP3A4CYP2C9CYP2C19CYP2C8 | |
| SCHEMBL14849051 | 0.77 | CYP46A1 (0.66) | CYP46A1CYP3A4CYP2C9CYP2C19CYP2C8 | |
| SCHEMBL22003286 | 0.74 | CYP46A1 (0.63) | CYP46A1CYP3A4CYP2C9CYP2D6TSHR | |
| SCHEMBL20792878 | 0.68 | CYP46A1 (0.49) | CYP46A1CYP3A4CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL18596681 | 0.67 | CYP46A1 (0.57) | CYP46A1CYP3A4CYP2C9CYP2C19CYP2C8 | |
| SCHEMBL14840218 | 0.60 | CYP46A1 (0.66) | CYP46A1CYP3A4CYP2C9CYP2C19CYP2C8 | |
| SCHEMBL14840643 | 0.58 | CYP46A1 (0.66) | CYP46A1CYP3A4CYP2C9CYP2C19CYP2C8 | |
| SCHEMBL14848961 | 0.57 | CYP46A1 (1.00) | CYP46A1CYP3A4CYP2C9CYP2C19CYP2C8 | |
| SCHEMBL16084040 | 0.57 | KMT2A (0.39) | CYP3A4CYP2C19ALDH1A1HPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190071455-A1 | 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | TAKEDA PHARMACEUTICALS CO (JP) | 2019-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190071455-A1 | 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PSEN1 | CYP46A1 3780/4885CYP3A4 4375/4885CYP2C9 4477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.